Status:
COMPLETED
Visnadine, Prenylflavonoids and Bovine Colostrum to Treat Vulvovaginal Atrophy in Postmenopausal Women
Lead Sponsor:
University of Messina
Collaborating Sponsors:
University of Victoria
University of Athens
Conditions:
Vulvovaginal Atrophy
Menopause
Eligibility:
FEMALE
45-70 years
Phase:
PHASE2
Brief Summary
The effects of a new vaginal cream containing visnadine (0.30%), prenylflavonoids (0.10%) and bovine colostrum (1%) will be evaluated in post-menopausal sexually active women affected by vulvovaginal ...
Detailed Description
Sexual health plays a key role during women's lives from puberty to post-menopausal period and, for this reason, it has increasingly received public health, pharmaceutical, and medical attention. Acco...
Eligibility Criteria
Inclusion
- postmenopausal sexually active women affected by vulvovaginal atrophy.
Exclusion
- relevant comorbidities (chronic cardiovascular, immune, endocrine and metabolic diseases and cancers);
- smokers;
- who used any other kind of pharmacologic treatment (including the substances tested in this study) in the previous 3 months.
Key Trial Info
Start Date :
December 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03281655
Start Date
December 1 2016
End Date
January 1 2018
Last Update
March 25 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.